Therapy

Sangamo Therapeutics

$16.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.44 (-2.72%) Today
+$0.26 (+1.65%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SGMO and other stocks, options, and ETFs commission-free!

About SGMO

Sangamo Therapeutics, Inc. Common Stock, also called Sangamo Therapeutics, is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA. The listed name for SGMO is Sangamo Therapeutics, Inc. Common Stock.

CEO
Alexander D. Macrae
Employees
354
Headquarters
Brisbane, California
Founded
1995
Market Cap
2.13B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.52M
High Today
$16.79
Low Today
$15.73
Open Price
$16.00
Volume
1.13M
52 Week High
$19.43
52 Week Low
$4.81

Collections

SGMO Earnings

-$0.37
-$0.23
-$0.10
$0.04
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 26, After Hours

You May Also Like

SNLN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure